Enfortumab vedotin may be a treatment option for patients with advanced head and neck cancer that is not amenable to definitive local therapy, researchers say. They reported phase 2 results with ...

Enfortumab vedotin targets Nectin-4, a therapeutic target highly expressed in multiple solid tumours, and like most other antibody-drug conjugates it works by delivering a toxic payload to cancer ...

in bladder cancer in general, there have been a lot of recent shifts in the landscape. So in the metastatic setting, as of about a year ago, the big change was the approval of enfortumab vedotin ...